EIKN (NASDAQ:EIKN) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Moderate Buy consensus from seven analysts (five buys, one hold, one sell) with an average 1‑year target price of $25.60.
• Analyst views diverge sharply — JPMorgan started coverage with an "overweight" rating and a $29 target, while Wedbush rates it "underperform" with a $7 target and Wall Street Zen recently downgraded to sell.
• Shares opened at $10.53 and were trading down 4.9%, with a 52‑week range of $9.93 to $17.40.

EIKN (NASDAQ:EIKN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $25.60.

Several equities research analysts recently weighed in on the company. Zacks Research raised EIKN to a "hold" rating in a report on Friday, February 27th. Cantor Fitzgerald initiated coverage on shares of EIKN in a report on Monday, March 2nd. They issued an "overweight" rating on the stock. JPMorgan Chase & Co. started coverage on shares of EIKN in a report on Monday, March 2nd. They set an "overweight" rating and a $29.00 price target for the company. Wedbush assumed coverage on EIKN in a research report on Thursday, February 26th. They set an "underperform" rating and a $7.00 target price on the stock. Finally, Wall Street Zen downgraded EIKN from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th.

EIKN Trading Down 4.9%

EIKN opened at $10.53 on Friday. EIKN has a 52 week low of $9.93 and a 52 week high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.